TMCnet News
VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNXREGULATED INFORMATION GHENT, Belgium, 24 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V. The above shareholder notified Ablynx that it has exceeded the 10% threshold on 19 January 2017 and now holds 6,148,362 Ablynx shares, representing 10.07% of the current 61,076,074 outstanding Ablynx shares, an increase from a former position of 5.40% (August 2016). Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code. Full versions of all transparency notifications are available on Ablynx website, under the section Investors. About Ablynx Ablynx is a biopharmaceutical company engaged i the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com. For more information, please contact Marieke Vermeersch Ablynx media/analyst relations Attachments: //www.globenewswire.com/NewsRoom/AttachmentNg/ad9a9547-5742-4564-a5fe-aeb173704865 |